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Mutational analysis of CYP1B1 gene in Pakistani pediatric 
patients affected with Primary Congenital Glaucoma 
Muhammad Umer Khan1,2,*, Raima Rehman3, Haiba Kaul3, Saqib Mahmood3, Ali Ammar3 
ackground: Glaucoma is the significant cause of blindness all over the world. Primary congenital 
glaucoma (PCG) reduces the vision and ultimately causes the blindness by damaging the aqueous 
drainage system of the eye. The purpose of the current study was to determine the pathogenic mutations 
in the CYP1B1 gene responsible for PCG. 
Methods: A total of thirty-five PCG patients were enrolled in this study. Blood samples were collected from the 
enrolled patients, and after DNA extraction and amplification, the coding regions of CYP1B1 were sequenced 
to determine the pathogenic mutations. In-silico analysis of the identified mutation was executed to study the 
effect of genetic variation on protein structure. 
Results: One mutation, c.1169 G>A has been revealed in exon 3 of the CYP1B1 gene leading to p.R390H, present 
in 20% of the patients enrolled. Besides, two missense sequence variants c.1294G>C (2 patients), c.1358A>G (4 
patients) and a synonymous variant c.1347T>C (18 patients) has also been observed.  
Conclusion: Our study not only reaffirms the role of CYP1B1 mutations in PCG but also supports the use of 
genetic screening for molecular diagnosis and carrier identification, which will reduce the burden of disease on 
society. Furthermore, the in-silico analysis of the identified mutations provided an in-depth understanding of 
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Introduction  
It is assessed that glaucoma causes the blindness or 
vision impairment in 6.9 million individuals while the 
overall 2.2 billion people have blindness [1]. It is a 
disorder in which death of retinal ganglion cells (RGC’s) 
occurs, usually due to high intraocular pressure, which 
leads to the atrophy of the optic nerve and results in 
gradual visual field damage and ultimately irreversible 
vision loss [2]. In general, primary congenital glaucoma 
(PCG), primary open-angle glaucoma (POAG) and 
primary angle-closure glaucoma (PACG) are the three 
main types of glaucoma [3]. Primary congenital, or 
infantile, glaucoma has onset within the one year of life. 
Approximately, it happens 1 out of 10,000 births, and 
reduced vision occurs in 10 percent cases [4]. According 
to a prevalence prediction study, it is estimated that 
over 11.1 million people will be bilaterally blind with 
PCG by 2020 [5]. 
 PCG is a condition without a cure that manifests 
itself in the recessive form. According to the data 
figures, it is estimated that nearly 13.5% of cases of 
blindness are due to glaucoma worldwide [6]. Primary 
open-angle glaucoma (POAG) occurs most commonly 
among different subtypes of glaucoma and causes more 
than 50% of the total glaucoma cases worldwide [7]. 
Primary congenital glaucoma (PCG) accounts for 0.01-
0.04% cases of blindness all over the world [8]. PCG is 
usually rare but is the common form of glaucoma in 
children often manifesting within the first three years of 
life. It has been observed that PCG is more prevalent in 
males as compared to females (65% versus 35%, 
respectively) and in 60-80% of cases patient’s both eyes 
are affected [3]. PCG has higher incidence rate in 
families where consanguinity is accustomed and in 
genetically inbred populations [9,10]. PCG is inherited in 
autosomal recessive mode, but some cases of pseudo 
dominance are also reported [11]. 
The pathophysiological mechanism of PCG is not 
fully understood. Increased IOP could compress the 
optic nerve at the lamina cribosa, block the axoplasmic 
flow, and interfere in retrograde transport of 
neurotrophin to RGCs [12]. Elevated IOP could also 
affect capillary blood supply to the region, and all these 
events could progressively lead to the apoptotic death of 
RGC’s. With Mendelian linkage approaches and mostly 
affected pedigrees, autosomal recessive PCG has been 
mapped to four chromosomal loci: GLC3A (2p21), 
GLC3B (1p36) GLC3C (14q24.3) and 14q24.2-q24.3 [12-
15]. Studies have reported CYP1B1 as a causal gene in 
PCG, and its mutations are reported in 27% of sporadic 
and 87% of familial cases of PCG [16]. The CYP1B1 gene 
is present at position 22.2 on the short (p) arm of 
chromosome 2, comprising of 3-exons encoding 543 
amino acids [3]. CYP1B1 protein belongs to CYP450 
superfamily of hemoproteins and is a membrane-bound 
monooxygenase with multiple functions [17]. It is 
present predominantly in the trabecular meshwork and 
neuroretina but also other tissues such as adrenal gland, 
kidney, uterus, and genitals both in adult and fetal life 
[18]. The protein is probably linked with the metabolism 
of those compounds that are critical for the 
development of the eye, but its exact role is still not 
known [19]. In the human eye, relatively high levels of 
CYP1B1 mRNA have been observed in the ciliary body 
and iris than retina, cornea, and retinal pigment 
epithelium [20]. 
This study was designed to find out the mutations of 
the CYP1B1 gene in PCG patients. 
Methods 
It is a descriptive study performed at the Biochemistry 
Department of University of Health Sciences, Lahore, 
during the period of March to December 2014. Thirty-
five PCG affected patients were recruited to participate 
in this study after the approval from the ethical 
committee of the institutional review board. Consent 
forms have been filled by the guardian of the patients. 
Complete medical history of all the patients was 
obtained. Ophthalmologists of   Layton Rahmatullah 
Benevolent Trust (LRBT) and Children Hospital 
confirmed the diagnosis of PCG. Blood samples of all the 
PCG affected individuals were collected in EDTA vials. 
DNA was extracted by a modified nonorganic method 
[21,22]. Four sets of primer pairs were designed to cover 
the two coding exons of CYP1B1 gene by using Primer 3 
genome Browser (Table 1).  
Amplification was performed in a 25μl reaction 
containing 50ng of genomic DNA, 2.5μl 1X PCR buffer, 
8pmoles of each primer, 2.5 mMdNTP, 2.5mM MgCl2, 
and 0.2U Taq DNA polymerase (Applied Biosystems). 
GeneAmp PCR System 9700 (Applied Biosystems) was 
used to amplify the desired region of CYP1B1 gene. 
Initial denaturation was done at 96°C for 7 minutes 
while 30 cycles (denaturation 95°C for 30s, annealing 
58°C for 45s, extension 72°C for 30s) were performed 
and a final extension of 10 minutes at 72°C was also 
done. 
Agarose gel (2%) was used to visualize the PCR 
products along with 100 bp molecular weight marker 
(ladder). Ethanol precipitation was done to purify the 
PCR product. The amplified DNA fragments were 
sequenced by fluorescence-based chain terminator 
(dideoxy) sequencing method on an ABI 3100 
Automated sequencer (Applied Biosystems). Finch Tv 
software was used to analyze the sequencing data. To 
look out for sequence alterations, the sequence of each 
exon from all the patients was blast against the normal 
CYP1B1 gene sequence using BLAST 2 (Basic Local 
Alignment Search Tool) sequences server on NCBI 




Exon    Primer Sequence 5`→3` Annealing 
temperature 
Product 
2 F GGCCATTTCTCCAGAGAGTC 66 0C 829bp 
2 R AACTCTTCGTTGTGGCTGAG 66 0C 829bp 
2 F ATGATGCGCAACTTCTTCACG 61.40C 754bp 
2 R CACTGTGAGTCCCTTTACCG 61.40C 754bp 
3 F ACTTGCTTTTCTCTCTCCACAT 60 0C                    505bp 
3 R TTGGACAGCACTATCAAGGAG 60 0C                    505bp 
3 F AACCAGTGGTCTGTGAATCAT 58 0C                    595bp 
3 R CCTGATGGACAGTTGATTTATG 58 0C                    595bp 
F forward, R reverse, bp base pairs 
Table 1: Primer sequences with their specific annealing temperature and PCR 
product size 
Statistical analysis 
Demographic and clinical data of all PCG patients were 
entered using PASW-22 (SPSS Inc. Chicago USA). 
Continuous variables were expressed as Mean ± SD; 
whereas categorical variables were in the form of 
frequency and percentages. The amplified DNA was 
sequenced, and the data was analyzed by using Chromas 
Lite v2.01 software. The sequence of each exon was blast 
against the normal reference sequence of SCN5A by 
using BLAST (Basic Local Alignment Search Tool) 
sequence server on NCBI website.  
Results 
Out of 35 patients enrolled in this study, 21 (60%) were 
male, and 14 (40%) were female. Mean age of patients 
was 9.61 ± 13.9 years (Mean ± S.D). Among them, 31 
(89%) patients were bilaterally affected by PCG, whereas 
the rest of the 4 (11%) patients were affected 
unilaterally. No eye abnormality other than PCG was 
associated with these patients. Family history of PCG 
was present in 14 patients (60%). Consanguinity was 
found in 30 patients (86%). Results of DNA sequencing 
for CYP1B1 gene revealed four sequence variations in 
the coding region of CYP1B1 gene. All of these 
variations were found in exon 3. All the variations 












Hom    Het 
g.8006G>A c.1169G> A 3 CGC>CAC p. R390H 7 0 Missense 
mutation 
g.8131G>C c.1294G>C 3 CTG>GGT p. L432V 2 0 Missense 
variant 
g.8184T>C c.1347T>C 3 GAT>GAC p.D449D 18 3 Synonymous 
variant 
g.8195A>G c.1358A>G 3 AAC>AGC p. N453S 4 0 Missense 
variant 
Hom homozygous, Het heterozygous 
Table 2: CYP1B1 sequence alterations identified by genomic analysis 
Seven patients (20%) revealed a mutation c.1169 G>A in 
exon 3 of CYP1B1 gene. Five of them were male, and two 
were female. All of these patients had consanguineous 
parents, and three of them showed a positive family 
history. This mutation altered the sequence of codon 
number 390 CGC for Arginine to CAC resulting in a 
Histidine creating a missense mutation (p.R390H). 
Figure 1 shows the representative chromatogram 
showing c.1169G>A mutation in exon 3 of the CYP1B1 
gene. 
 
Table 3: Clinical features of PCG patients with the p.R390H mutation 
 
Figure 1: Chromatogram showing c.1169G>A mutation in exon 3 of the CYP1B1 gene. 
(a mutation, b normal) 
 
Figure 2: Multiple sequence alignment of CYP1B1 proteins from various species 
showing arginine residue is conserved in all species. 
A substitution of T>C was observed at nucleotide 
position c.1347 in exon 3 of the CYP1B1 gene. However, 
this change in DNA nucleotide sequence did not result 
in an amino acid change (GAT>GAC Aspartic 
acid>Aspartic acid). It is polymorphism and was found 
in homozygous state in 18 patients (51%) in this study. 
Also the same polymorphism in heterozygous condition 
was found in 3 patients (8%). Another SNP (single 
nucleotide polymorphism) AAC-to-AGC was found at 
position c.1358 in four cases. It replaced codon number 
453 for Asparagine (AAC) into a Serine (AGC) resulting 
in a polymorphism. Sequencing analysis of exon 3 of the 
CYP1B1 gene showed another polymorphism in two 
patients (6%). This change occurred due to C>G at 
position c.1295 resulting in codon 432 CTG-to-GTG 
(Leu-to-Val).  
In silico analysis  
In silico analysis has been performed to determine the 
pathogenic effect of p.R390H mutation. SIFT software 
was used to evaluate the effect of c.1169 G>A mutation 
on protein function (http://sift.jcvi.org/). It revealed a 
score of 0.0001 for p.R390H. The SIFT score of less than 










PCG-1 Male 14 By birth Bilateral Yes present 29 
PCG-2 Male 7 By birth Bilateral Yes present 31 
PCG-10 Female 1.5 By birth Bilateral No present 33 
PCG-21 Male 34 By birth Bilateral Yes present 28 
PCG-23 Male 2 By birth Bilateral No present 32 
PCG-33 Female 1.5 By birth Unilateral No present 33 
PCG-34 Male 29 By birth Bilateral No present 32 
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Therefore, it is suggested that substitution at codon 390 
from R to H is harmful for the protein function. So SIFT 
postulated that p.R390 has a vital role in CYP1B1 protein 
structure and ultimately its proper function.   
Clustalw2.1 (http://www.ebi.ac.uk/Tools/services) 
was used to perform the multiple sequence alignment of 
CYP1B1 among various species. Arginine at position 390 
is found to be conserved in the CYP1B1 protein among 
different species, emphasizing its importance in protein 
molecule (figure 2). 
PolyPhen2 was also used to predict the pathogenic 
role of c.1169G>A mutation  which was based on 
physical and comparative considerations. 
(http://genetics.bwh.harvard.edu/cgibin/ggi/ggi2.cgi). 
This web tool predicted this mutation to be pathogenic 
with a score of 1.00 (figure 3). 
 
Figure 3: Polyphen-2 report for R390H depicted the deleterious effect 
Model building and structure analysis 
A 3D model was built to study the protein-level 
mechanisms of the p.R390H mutation for a 
bioinformatics structural analysis by using I-TASSER 
(Figure 4). 
 
Figure 4: Structural changes induced by the p.R390H missense mutation in a 
conserved domain of the CYP1B1 protein near the active site. 
A ribbon diagram of the CYP1B1 protein is shown on 
the right with heme group of the active site in red sticks 
while ligand (α-Naphthoflavone) in the yellow sticks 
with polar contacts as blue circle indicates the location 
of the p.R390H mutation. Inserts A and B compare the 
H-bonding situation and resultant conformational 
changes due to the p.R390H mutation. Arg390 lies close 
to the active site of CYP1B1 enzyme, its substitution by 
the His results in the loss of structuring H-bonds (dotted 
lines) with Glu387, Asn428, Pro437, and Asn439. Amino 
acids involved in hydrogen bonding are shown as sticks 
(distances also indicated) with C atoms for R390 in grey, 
N atoms in blue, O atoms in red and S atoms in orange 
respectively. 
R390H cause the parallel orientation of the Glu387 
and His390 residues side-chain-interaction to change to 
the end of Asn428 in mutated form while the helical K 
domain of CYP1B1 protein in wild type showed the 
analogous arrangement of side chains of Glu387 and 
Arg390. It forms a hydrogen-bonding interaction with 
the turn-apart meander region end of Asn428, so it is 
considered that this structure is required for haem 
binding and overall proper functioning of the molecule. 
Discussion  
Primary congenital glaucoma is due to the pathogenic 
mutations of CYP1B1 [3]. In the current study, out of 35 
PCG patients enrolled, 21(60%) were male, and 14(40%) 
were female.  These results are following the results of a 
study conducted by Vasiliou and Gonzalez, who reported 
that PCG is more prevalent in males (65%)  as compared 
to females (35%) [3]. Frequency of PCG causing CYP1B1 
mutations varies among different populations ranging 
from less than 10% to 100% [11,23-26]. In current study, 
CYP1B1 mutations were found in 20% (7/35) of the 
patients, which is comparable with the prevalence of 
CYP1B1 mutations in  China (17.2%) [27], in Indonesia 
(33.3%) and in Europe (22.2%) [26]. Higher results are 
reported in the Indian (44%) and the Iranian population 
(70%) [28]. 
 In the present study, 43% of patients harbouring 
CYP1B1 mutations showed family history of PCG, 
whereas another study reported that 87% of familial 
PCG cases are due to mutations in this gene [17]. Many 
studies said that CYP1B1 mutations are more common 
in populations where consanguinity is customary [29]. 
In current study, 100% of PCG patients harbouring 
CYP1B1 mutations had consanguineous parents. These 
results are in accordance with another study conducted 
in Saudi Arabia where among PCG patients, prevalence 
of CYP1B1 mutation ranged from 70% to 100% in 
consanguineous and inbred populations [30]. As 
Pakistani population is highly consanguineous, PCG 
segregating itself in recessive form is often seen in 
pediatric ophthalmic clinics. That’s why this study was 
planned to screen children affected by PCG and identify 
the underlying molecular defect. Previously, mutation 
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in genes including CYP1B1 has been reported in 
Pakistani patients [31,32]. 
 In the current study, sequencing analysis revealed 
one mutation R390H in seven patients, i.e. in 20% of the 
patients. These results are quite comparable with other 
studies that revealed 16% and 19.2%  R390H mutations 
in CYP1B1 in PCG patients among Indian and Iranian 
population respectively [28,33]. Another study revealed 
p.R390H was the most common mutation in the 
Pakistani population accounting for 25% of (5/20) of the 
families with PCG [34]. 
 In our study, all patients who harboured the c.1169 
G>A mutation were homozygous, and one of these 
patients was unilaterally affected while rest were 
bilaterally affected by birth. These results are similar to 
findings of the study conducted in Iran and India that 
revealed all patients who harbour the c.1169 G>A 
mutation was homozygous showing clinical features and 
disease severity of varying degrees [28,31]. Thus, 1169 
G>A has been reported to show variable phenotypes in 
various populations. Unknown environmental and 
genetic factors may be involved in the above mentioned 
variable clinical manifestations of CYP1B1 mutations. 
The arginine (R) 390 residue is present in the 
conserved domain of alpha-helix K domain of CYP1B1 
and thus is vital for the normal functioning of the CYPB1 
protein [20]. The mutation c.1169 G>A (p.R390H) alters 
the side-chain physiognomies from linear guanidinium 
group to imidazole ring and disturbs the establishment 
of salt bridges on the ‘meander’ region [20].  
 Two missense sequence variants c.1294G>C and 
c.1358A>G  carried by two and four patients 
respectively; in addition to the mutation mentioned 
above, were also observed in current research work. Both 
of these variations are previously reported and are 
considered as polymorphisms as not associated with the 
disease [25,28]. Besides a synonymous variant 
c.1347T>C was also found in the current study. However, 
this change in DNA nucleotide sequence does not result 
in an amino acid change (GAT>GAC Aspartic acid> 
Aspartic acid). This sequence variant was found in the 
homozygous state in 18 patients and 3 patients in 
heterozygous form.  This CYP1B1 polymorphism 
variation is reported previously [25,28]. 
Our findings conclude that CYP1B1 mutation is one 
of the leading cause of PCG. Molecular characterization 
of c.1169 G>A (p.R390H) mutation using in-silico tools 
may help to understand the underlying pathology of the 
disease. These results will be beneficial and helpful in 
the diagnosis, treatment of PCG patients. The 
identification of the molecular cause of PCG will provide 
better ways of genetic counselling under or at 
reproductive age. Characterisation of CYP1B1 
mutations may help to implement genetic analysis 
services for patients with PCG, and the genotype-
phenotype correlation will aid in better management for 
the disease. 
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